Trial site
Ottawa
Ottawa, Ontario K1N 5C8, CanadaNot linked to an institution yet
- 15running trials
- 2closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 24 trials
- Phase 41 trial
- Status
- Active, not recruiting9 trials
- Recruiting6 trials
- Completed1 trial
- Withdrawn1 trial
- Lead sponsor
- Novartis Pharmaceuticals17 trials
Running trials
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642· Phase 2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Modifying PEST for Psoriatic Arthritis Screening
NCT06382051· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
NCT06733922· Phase 4· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381· Phase 2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722· Phase 3· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error